-
Dr Mascarenhas on Key Considerations for Clinical Trial Enrollment in Myelofibrosis
30 Jul 2025 03:41 GMT
… , a professor of medicine at the Icahn School … Excellence for Blood Cancers and Myeloid Disorders, … survival prolongation as a treatment goal.
Therapeutic decisions … trial participation.
Mascarenhas also highlighted key considerations for the use of imetelstat …
-
IMpact-MF Trial Aims to Show OS Benefit of Imetelstat in Relapsed Myelofibrosis
29 Jul 2025 19:19 GMT
… the Icahn School of Medicine at Mount Sinai and … Leukemia Program at The Tisch Cancer Institute in New York, … 3 trial, and what differentiates imetelstat from currently available treatment options … not great candidates for a drug like this. The cytopenias …
-
Quality of Life, Caregiver Impact Key to Future Imetelstat Research in Lower-Risk MDS: María Díez Campelo, MD, PhD
20 Jul 2025 20:40 GMT
… (MDS) Treated With Imetelstat in the IMerge Trial," which she … life findings influence real-world treatment decisions for patients with … patient and also for the doctor to bridge this world.
… patients not responding to the drug. The benefit is clearly …
-
Imetelstat Linked to Sustained Health-Related Quality-of-Life Benefits in Lower-Risk MDS: María Díez Campelo, MD, PhD
18 Jul 2025 10:06 GMT
… Myelodysplastic Syndromes Treated With Imetelstat in the IMerge Trial," which she … of patients who responded to treatment.
Watch part 1 to learn … is clearly associated [with] the drug, not with the responding patients …
-
Evaluating Imetelstat's Impact on Health-Related Quality of Life in Lower-Risk MDS: María Díez Campelo, MD, PhD
16 Jul 2025 22:04 GMT
… Syndromes Treated With Imetelstat in the IMerge Trial," which she … different organ functions. All treatments that we are going to … an end point in clinical trials.
Building on that, what … , with a placebo-controlled trial with imetelstat (Rytelo; Geron) in …
-
Future Perspectives in LR-MDS: Addressing Unmet Clinical Needs and Treatment Challenges
11 Jul 2025 12:15 GMT
… notes that while new treatments like luspatercept and imetelstat offer hope beyond …
-
Lower-Risk MDS Treatment Paradigms and Considerations for Transfusion and Pharmacologic Therapies
09 Jul 2025 16:15 GMT
… of care. Current National Comprehensive Cancer Network guidelines reflect these advances … FDA approval of imetelstat in June 2024, based on the global IMERGE trial … .
For ring sideroblast–negative patients, treatment options include ESAs (for baseline …
-
Evolving Treatment Paradigms in Lower-Risk MDS: Current Therapeutic Options and Mechanistic Approaches
07 Jul 2025 14:47 GMT
… agents (ESAs), luspatercept, and imetelstat offer tailored treatment options for anemia in …
-
Myelodysplastic Syndrome Market Epidemiology Report 2025-2035: Pipeline Therapies, Drugs Sales, and Regional Outlook
06 Jul 2025 13:24 GMT
… luspatercept and imetelstat illustrate how … drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug …
Pfizer
Astex Pharmaceuticals
Acceleron Pharma … cancer-epidemiology-report-in-market-drugs-treatment …
-
IMerge Trial
01 Jul 2025 13:20 GMT
… from the IMerge phase 3 trial of imetelstat in lower-risk myelodysplastic … for a sequential, patient-centered treatment approach to enhance quality of …
About
© 1995-2025